Clinical Trial Update: A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1b/2a clinical trial evaluating Nadunolimab in combination with azacitidine, with or without venetoclax, for myelodysplastic syndrome and acute myeloid …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Nadunolimab (nadunolimab)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndrome(MDS), Acute Myelogenous Leukemia (AML) | Phase 1, Phase 2 | Status: RECRUITING